Prothena (PRTA) Earnings Analysis
Prothena (PRTA) next reports earnings on 2026-08-03, consensus EPS -0.39 USD. Last quarter (2026-05-07) it beat with EPS 0.6 USD vs -0.31 USD est (+293.5%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -3.00.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PRTA next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | -0.39 USD |
| Revenue estimate | 0.00B |
PRTA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.6 USD | -0.31 USD | +293.5% | Beat |
| 2026-02-19 | -0.44 USD | -0.45 USD | +2.2% | Beat |
| 2025-11-06 | -0.67 USD | -0.6 USD | -11.7% | Miss |
| 2025-08-04 | -1.86 USD | -1.11 USD | -67.6% | Miss |
| 2025-05-08 | -1.12 USD | -0.92 USD | -21.7% | Miss |
| 2025-02-20 | -1.08 USD | -1.02 USD | -5.9% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
PRTA valuation and analyst view
| Trailing P/E | -3.00 |
|---|---|
| Trailing EPS | -2.81478 USD |
| Price / book | 1.45 |
| Dividend yield | 0.00% |
| Market cap | 0.45B |
| Analyst consensus | Buy (20 buy / 6 hold / 2 sell) |
| Avg price target | 22.86 USD |
Related research pages
Frequently asked questions
When is Prothena (PRTA)'s next earnings date?
Prothena is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -0.39 USD and revenue estimate of 0.00B.
Did PRTA beat earnings last quarter?
In its 2026-05-07 report, PRTA posted EPS of 0.6 USD versus a -0.31 USD estimate — a beat of 293.5%.
What is PRTA's earnings track record?
Over the last 6 reported quarters with consensus data, PRTA beat estimates 2 times (33%).
What is PRTA's current P/E ratio and EPS?
PRTA trades at a trailing P/E of -3.00 on trailing EPS of -2.8147761972145675 USD.
What do analysts rate PRTA?
Analyst consensus is "Buy" across 28 ratings (0 strong buy, 20 buy, 6 hold, 2 sell, 0 strong sell). Average 12-month price target: 22.86 USD.